Acceleron Pharma

Investors & Media

Press Releases

Date Title and Summary
Toggle Summary Acceleron to Webcast Second Quarter 2020 Operating and Financial Results on August 6, 2020
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 27, 2020-- Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, August 6, 2020 at 5:00 p.m. EDT to discuss its second quarter 2020 operating and financial results.
Toggle Summary Acceleron Announces Closing of Public Offering of Common Stock and Exercise of Underwriters’ Option to Purchase Additional Shares
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 7, 2020-- Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that it has issued an aggregate
Toggle Summary Acceleron Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 30, 2020-- Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that it has priced an
Toggle Summary Acceleron Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 29, 2020-- Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that it intends to offer and
Toggle Summary European Commission Approves Reblozyl (luspatercept) for the Treatment of Transfusion-Dependent Anemia in Adult Patients with Myelodysplastic Syndromes or Beta Thalassemia
Reblozyl regulates late-stage red blood cell (RBC) maturation to potentially reduce or eliminate the need for regular RBC transfusions Reblozyl is the first and only erythroid maturation agent to be approved in the European Union , representing a new class of therapy PRINCETON, N.J.
Toggle Summary Acceleron Presents Topline Results of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial Hypertension
- Data presented during ‘Breaking News’ Session of the American Thoracic Society 2020 Virtual Conference (ATS 2020 Virtual) show the PULSAR trial achieved its primary endpoint: a statistically significant mean reduction in pulmonary vascular resistance (PVR) - - Patients on stable background
Toggle Summary Acceleron to Host Conference Call and Webcast to Review Results of PULSAR Phase 2 Trial of Sotatercept Presented at American Thoracic Society 2020 Virtual Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 22, 2020-- Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced it will host a conference call
Toggle Summary Acceleron Appoints Christopher Hite to its Board of Directors
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 4, 2020-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today the appointment of Christopher
Toggle Summary Acceleron Announces Presentations on REBLOZYL® (luspatercept-aamt) at the 2020 American Society of Clinical Oncology and European Hematology Association Virtual Annual Meetings
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 20, 2020-- Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that a total of six distinct
Toggle Summary Acceleron Announces Oral Presentation of PULSAR Phase 2 Trial Results in Virtual American Thoracic Society 2020 Conference Session on June 24, 2020
Acceleron to host an investor and analyst webcast and conference call following the virtual ATS 2020 presentation on June 24 th CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 19, 2020-- Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and